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Abstract
Individuals with partial HSA21 trisomies and mice with partial MMU16 trisomies containing an extra copy of the DYRK1A
gene present various alterations in brain morphogenesis. They present also learning impairments modeling those
encountered in Down syndrome. Previous MRI and histological analyses of a transgenic mice generated using a human YAC
construct that contains five genes including DYRK1A reveal that DYRK1A is involved, during development, in the control of
brain volume and cell density of specific brain regions. Gene dosage correction induces a rescue of the brain volume
alterations. DYRK1A is also involved in the control of synaptic plasticity and memory consolidation. Increased gene dosage
results in brain morphogenesis defects, low BDNF levels and mnemonic deficits in these mice. Epigallocatechin gallate
(EGCG) — a member of a natural polyphenols family, found in great amount in green tea leaves — is a specific and safe
DYRK1A inhibitor. We maintained control and transgenic mice overexpressing DYRK1A on two different polyphenol-based
diets, from gestation to adulthood. The major features of the transgenic phenotype were rescued in these mice.
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Introduction
Phenotype mapping, based upon comparisons between geno-
types and phenotypes of partial trisomy 21, has revealed that some
regions of HSA21 may contain genes involved in specific
phenotypes characteristic of Down syndrome (DS) including
mental retardation. One such region, DCR-1 [1,2], contains 19
genes, one of which — DYRK1A [Dual specificity Tyrosine(Y)
Regulated Kinase 1A] — is closely associated with Down
syndrome phenotypes. A recent study describes a mother and
two children presenting a facial phenotype characteristic of DS
and with moderate mental retardation. These individuals carry a
small duplication of 10 genes including DYRK1A, consistent with
a role for DYRK1A as a candidate gene in Down syndrome [3].
DYRK1A is a mammalian ortholog of minibrain in drosophila
[4], a gene which is essential for normal postembryonic
neurogenesis [5]; as its name implies, the DYRK1A enzyme has
dual substrate specificities: autophosphorylation for self activation
takes place on the tyrosine-321 residue in the active loop of the
catalytic domain [6] and target protein phosphorylation occurs on
serine/threonine residues. Many targets have been identified in
vitro including FKHR, dynamin1, amphiphysin and tau protein
[7,8,9]. These findings suggest that DYRK1A is a major player in
both cell cycle regulation and synaptic plasticity. DYRK1A levels
in the brains of DS subjects with free trisomy were found
approximately 1.5-fold higher than those in normal subjects
indicating that this protein is overproduced in a gene dosage-
dependent manner in Down syndrome [10].
Murine models with partial MMU16 trisomies such as Ts65Dn,
Ts1Cje or human HSA21 — all carrying extra copies of several
genes, including the DYRK1A gene — have been generated.
These models present morphogenesis defects in the cranium and
brain [11,12], together with learning and memory defects [13],
detectable in such paradigms as the Morris water maze [14] or
object recognition [15] tests. Mice carrying a smaller duplication
with 33 genes, encompassing the gene encoding DYRK1A,
present brain alterations but do not display abnormal behavior
in the Morris water maze. However, deletion of the same region in
a model with partial MMU16 trisomy, Ts65Dn, corrects the
cognitive deficits seen in the Ts65Dn mice [16]. These results
strongly suggest that duplication of genes from this region is
necessary to produce the learning impairment seen in the Ts65Dn
model of Down syndrome. Transgenic mice have also been
developed using a yeast artificial chromosome from this region
(YAC 152F7). cDNA mapping experiments [17] and human
genome sequencing [18] showed that YAC152F7 contains five
genes: PIGP, TTC3, DSCR9, DSCR3 and DYRK1A. This
murine model presents both brain abnormalities and learning
impairments [19,20,21]. On the contrary, transgenic mice for the
YAC 141G6 bearing extra copies of all genes included in YAC
152F7 except for DYRK1A did not display any brain or
behavioural alterations. Similar phenotypic alterations have been
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human DYRK1A and with a murine BAC clone carrying only
murine Dyrk1a (data not shown). In a previous study, using
regional MRI, we found that morphological alterations through-
out the brain in the YAC tg152F7 were not uniform: the total
brain volume was 14% greater in transgenic mice than in wild-
type mice, with an effect 2,5 greater (25%/10%) in the ventral
region (including the thalamic-hypothalamic region) than in the
cortex (10% greater volume) [23]. Unbiased stereological cell
counts of NeuN-positive neurons revealed a greater cell density in
the thalamic-hypothalamic area and a lower cell density in the
somatosensory cortex in transgenic mice than in wild-type mice.
These results indicate that the phenotypic effects of overexpressing
the DYRK1A gene in the brain differ in a region-specific manner.
These morphological alterations are inverse with those described
in a model with heterozygous deletion of Dyrk1a [24] (including a
smaller brain volume than in wild-type mice, particularly in the
ventral region). The invalidated heterozygous model also displays
learning impairments and an altered pyramidal cell phenotype
[25].
We investigated the possibility of correcting these phenotypes
through modulation of DYRK1A activity. Bain and colleagues
described the properties of 30 inhibitors, tested with 25 different
kinases: one of the most specific inhibitors of DYRK1A was
epigallocatechin gallate, with an apparent IC50 of 0.33 mM [26].
DYRK1A inhibition by EGCG was also demonstrated in NIH3T3
cells and a mutation analysis indicated a mechanism involving a
non competitive inhibition [27]. EGCG can cross the blood-brain
barrier [28] and the placental barrier [29]. EGCG is the major
catechin in green tea leaves (40 to 50% of the total catechins
amount). Indeed, feeding a green tea drink to mice (usually
drinking 3–5 ml/day) is equivalent to administering 0.6 mg/day
pure EGCG, which is effective in the treatment of 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease
(MPTP), through its effects on dopaminergic neurons [30].
We maintained mice on two polyphenol-based diets from
gestation to adulthood. Using the phenotypic tools that we have
previously designed we compared the effects of these diets on
batches of control and transgenic animals.
Results
Link between the Dyrk1a gene copy number and the
brain phenotypes
We generated double transgenic mice by crossing YACtg152F7
with Dyrk1a (+/2) mice. Resultant double transgenic mice had
normal levels of DYRK1A mRNA in the brain (Fig 1A) and a
corrected body weight (data not shown); MRI analyses revealed a
corrected brain volume and a corrected regional morphology
(fig 1B). Figure 1C shows a linear regression analysis of the
relationship between brain volume and Dyrk1a gene copy
number.
GTP (Green tea polyphenols) diet and brain
morphogenesis
Thus brain volume is regulated by DYRK1A gene copy
number. Indeed inhibiting the activity of DYRK1A may
counteract the phenotypic effects of its overexpression.
We used a green tea infusion, which was prepared daily. Mice
were maintained on this diet from gestation (started during initial
mating period) and through adulthood, until they were killed for
examination. The study included four groups of mice: wild-type
(wt) and transgenic (tg), fed with water or with green tea. The
active compounds in green tea infusions are thought to be
predominantly polyphenols and caffeine, which is less abundant in
green tea than in black tea [31].
The amount of the protein dyrk1a in samples prepared from
dissected hypothalamus-thalamus region was assessed by western
blot analysis for the four groups of animals: this amount is not
modified by the diet.(fig 2A and B)
We assessed total brain volume using in vivo MRI and
determined brain weight after dissection (fig 3). Brains from
transgenic mice fed with green tea were 7.1% heavier, and had
7.5% greater volume, than wild-type mice green tea fed; the
transgenic fed water had 13.2% heavier brains, with 15% greater
volume than wt water fed. The regional volume of the thalamic-
hypothalamic region was 24.4% greater in water-fed YACtg152F7
mice as compared to WT, and only 9% greater in green tea-fed
YACtg152F7 mice as compared to WT. There are small but
significant differences in brain weight and volume of the thalamus-
hypothalamus region between water-fed and green tea-fed wild-
type mice. Two-way ANOVA revealed significant effects of
genotype and treatment and an interaction between treatment
and genotype effect (supplementary table 1 in Data S1).
GTP diet and learning deficit
A learning deficit was also observed in murine models
overexpressing the DYRK1A gene, using the Morris water maze
with direct and reverse platform paradigms. These defects may
indicate a long-term memory deficit. We used two paradigms,
spontaneous alternation in the Y–maze and object recognition, to
assess the effects on short-term and long-term memory, respec-
tively [32,33]. The Y-maze consists of three arms, each of which
the animal is free to visit. The rate of spontaneous alternation
(visiting each arm in turn) was greater than 50% for each of the
four groups. Similar findings were obtained for both of two test
sessions (number of alternations/total number of possible
alternations 6100 (AS1), fig 4A), indicating all mouse groups
had similar levels of working memory. Additionally, the number
of entries did not differ between the first and the second halves of
the first session, between the first and second sessions and
between groups of mice. This demonstrated both short-term
habituation and long-term habituation of the mice, neither of
which were affected by treatment or genotype. In the object
recognition test, each mouse is placed individually in an open-
field setting, in which one object is placed at the left-hand side
and a second object at the right-hand side. The test comprises
five daily sessions. After the training sessions one object is
substituted for a novel object. Exploration time was lower with
the transgenic mice than with wild-type mice, and lower with
GTP-treated mice than with water-fed mice during both the
acquisition and retention sessions. Wild-type animals showed a
clear long-term memory acquisition during the retention session.
By contrast, the memory index 1006(N2F/N+F) was close to
zero for water-fed transgenic animals: these animals were unable
to recognize object novelty in the object recognition task. The
GTP-treated transgenic mice showed discrimination indices
equivalent to that of wild type mice (fig 4B). The main
constituents of green tea infusion are catechins and caffeine.
We used purified polyphenols from green tea (polyphenon 60;
see composition in sup Table III) to assess the effect of a purified
compound. This second experiment incorporated three groups
of mice: water-fed controls, polyphenon-treated controls and
polyphenon-treated transgenic mice. Each of the three groups
had similar exploration times in the novel object recognition
paradigm and recognized the novel object, demonstrating similar
object novelty discrimination behavior (fig 4C).
GTP Rescue of Brain Phenotypes
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The ability of animals to learn and remember may be encoded
at the synaptic level: synaptic plasticity has been linked to various
factors including levels of the neurotrophic factor, BDNF [34,35].
We used quantitative RT-PCR to measure BDNF mRNA levels in
hippocampi of human fetal brains from individuals with trisomy
21 and from age-matched diploid individuals (19–21 weeks) to
determine potential BDNF deficiency in trisomy 21 patients.
BDNF mRNA levels were 50% lower in these patients than in age-
matched diploid individuals (Fig 5A). BDNF transcription is
regulated by CREB [36]. We have previously found low levels
pCREB in the brains of YACtg152F7 mice [20]. In this study, we
compared BDNF mRNA levels in hippocampi from transgenic
mice with those from water-fed wild-type mice and BDNF mRNA
levels of GTP-fed tg with wt mice. Tg mice had a lower level of
BDNF in the hippocampus than wt mice; this defect was corrected
Figure 1. Phenotypic correction by genotype correction of DYRK1A copy number. Wild type (WT), YACtg152F7 transgenic (TG), dyrk1a (+/
2) (HT) and double transgenics (TGxHT) generated by three different crossings. A: brain DYRK1A mRNA levels determined by quantitative PCR; B: in
vivo MRI assessment of total brain volume (mm
3); ** for p,0.01. (Mann-Whitney-Wilcoxon test; statistical significance considered to be p,0.05); C:
linear regression analysis of brain volume and DYRK1A gene dosage. (R2=0.977).
doi:10.1371/journal.pone.0004606.g001
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the BDNF plasma membrane receptor, TRKB, were significantly
lower in YACtg152F7 mice than in wt mice. This defect was also
corrected by GTP treatment (Fig 5C).
Discussion
In this study we have shown that modulation of the DYRK1A
gene copy number can correct brain morphogenesis alterations. It
is possible to compensate the deficit in murine Dyrk1a heterozy-
gote by the addition of one copy of human DYRK1A; the
correction operates also on the phenotypes seen in the
YACtg152F7 model and induced by the overexpression. These
results established Dyrk1a as a key player in control of brain
development and brain morphogenesis: the brain volume, as
shown by MRI experiments is strongly related to Dyrk1a gene
copy number (Fig 1C). We also demonstrated that chronic
administration of polyphenols from green tea can have a similar,
although less efficient than normalizing the gene copy number,
corrective effect on brain alterations indicating that the diet is
bringing the level of active DYRK1A to a value between the
values produced in the transgenic and the wild type situations. The
effect of the polyphenols is also visible when comparing water fed
and green tea fed wild type animals: the diet induces a significant
reduction of brain weight and thalamus-hypothalamus volume
suggesting that the diet induced reduction of active Dyrk1a is
Figure 2. Average DYRK1A protein levels in thalamus-hypothalamus for each genotype-treatment group. A: western blot assessment
of dyrk1a and actin levels; B: average Dyrk1a protein levels for wild type (WT, n=6), YACtg152F7 transgenic (TG, n=6) water-fed (H2O) and in wild
type (WT, n=3), YACtg152F7 transgenic (TG, n=7) green tea-fed (GTP). ** for p,0.01.
doi:10.1371/journal.pone.0004606.g002
Figure 3. Effect of GTP treatment on DYRK1A-induced brain alterations. A: weight of total brain (mg) in wild type (WT, n=26), YACtg152F7
(TG, n=13) water-fed (H2O) and in wild type (WT, n=13), YACtg152F7 transgenic (TG, n=18) green tea-fed GTP; B: in vivo MRI assessment of total
brain volume (mm
3) in wild type (n=10) and YACtg152F7 transgenic (n=10) water-fed (H2O) and in wild type (n=9) and YACtg152F7 transgenic
(n=11) green tea-fed GTP; C: in vivo MRI assessment of hypothalamus-thalamus volume (mm
3) in wild type (n=6) and YACtg152F7 transgenic (n=6)
water-fed (H2O) and in wild type (n=5) and YACtg152F7 transgenic (n=7) green tea-fed (GTP). (Details of the MRI experiments in supp. data). ** for
p,0.01; * for p,0.05.
doi:10.1371/journal.pone.0004606.g003
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treatment had no effect on the results to the spontaneous
alternation paradigm: transgenic animals do not show any
impairment for this task and behave similarly to the control
animals. Using a novel object recognition paradigm to assess long
term memory, transgenic mice with three copies of DYRK1A
were clearly impaired: polyphenol treatment ameliorates cognitive
deficits in tgYAC152F7 mice. Other groups have shown an effect
of polyphenols on brain functions: in a study designed to
determine whether cognition could be influenced by a flavanol-
rich diet, Van Praag et al [37] found that memory, hippocampal
vascularisation and neuronal spine density were enhanced in mice
fed a (-)epicatechin-containing diet compared with controls. The
polyphenol treatment does not modify the amount of DYRK1A
protein. Our results suggest either a direct effect of EGCG on the
activity of DYRK1A or an indirect effect, acting via a downstream
Figure 4. Effect of GTP treatment on short- and long-term memory. In wild type (WT, n=10) and YACtg152F7 transgenic (TG, n=10) water-
fed (H2O) and in wild type (WT, n=10) and YACtg152F7 transgenic (TG, n=10) green tea-fed (GTP, n=10). A: Spontaneous alternation test with two
sessions of ten minutes each separated by 24 h: number of alternations/total number of possible alternations6100 (AS1). B: Object recognition test:
difference in exploration time between the new and familiar objects, in percentage of total time spent exploring the two objects; 1006(N2F/N+F). **
for p,0.01, * for p,0.05. according to Wilcoxon test results (two-way ANOVA in supplementary data). C: Object recognition test on WT H2O-fed
(n=10), WT polyphenon-fed (n=10) and TG polyphenon-fed (n=6) (no significant differences between the three groups).
doi:10.1371/journal.pone.0004606.g004
Figure 5. Effect of GTP treatment on BDNF and TRKB mRNA levels. mRNA levels determined by quantitative PCR. A: BDNF in fetal human
hippocampus (EU: normal karyotype (n=4) and T21: trisomy 21 (n=5); B: BDNF in adult hippocampus from wild type (WT; n=6), YACtg152F7
transgenic (TG; n=10), water-fed (H2O) WT (n=8), TG (n=3), green tea-fed (GTP); C: TRKB in adult hippocampus from wild type (WT; n=4),
YACtg152F7 transgenic (TG; n=18), water-fed (H2O) WT (n=4), TG (n=4) green tea-fed (GTP). ** for p,0.01; * for p,0.05.
doi:10.1371/journal.pone.0004606.g005
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endocytic proteins has been observed in cell cultures: this
phosphorylation modifies the interactions of dynamin 1, synap-
tojanin 1 and amphiphysin 1 with other members of the
endocytic accessory proteins and potentially regulates the
assembly of protein complexes. Additionally, EGCG treatment
in HEK 293 cells results in decreased phosphorylation of
amphiphysin, a DYRK1A target [8]. Modulation of these
trafficking proteins is generally thought to influence synaptic
plasticity. LTP and its opposing process, long-term depression,
are widely considered the major cellular mechanisms that
underlie learning and memory. LTP was reduced and LTD
was augmented in comparison to diploid controls in the isolated
hippocampus of Ts65Dn and Ts1Cje, two DS murine models
carrying a partial trisomy 16 encompassing the DYRK1A gene
[38,39,40]. LTP levels can be rescued in hippocampal slices from
Ts65Dn mice by EGCG treatment [41]. This is consistent with
our observations of long-term memory impairment rescue. These
effects may be due to EGCG action on DYRK1A resulting in
modulation of the endocytic apparatus and/or modulation of
BDNF-related pathways. BDNF is one of the neurotrophins
involved in the regulation of neuron survival and differentiation;
it has also acute effects on synaptic transmission. It has been
proposed that it acts as a modulator of GABAergic inhibition
[42]. In hippocampal slices synaptic inhibition was enhanced by
reduced BDNF expression in bdnf+/2 animals [43]. Further
experimentation will be needed to elucidate effects of timing of
treatment on the various phenotypic outcomes. Although
correction of morphogenesis defects may require an early
treatment, treatment during adulthood may result in improve-
ment of cognition performance; indeed, this was recently
demonstrated using GABAa receptor antagonists [15]. However
it should be also mentioned the EGCG is a potent antioxidant
and a free radical scavenger and has protective effects in ischemia
[44] and in atherosclerosis [45]. It can decrease the amyloidosis
in the brain by acting on APP processing [46]. Therefore other
EGCG targets may explain the observed rescue of phenotypes
that are primarily caused by the overexpression of Dyrk1a.
Nevertheless our results suggest a central role for Dyrk1a in CNS
functioning and highlight a potential clinical benefit of DYRK1A
inhibitors, particularly of natural polyphenol extracts; these
extracts are already used as dietary supplements for the treatment
of other disorders and have been shown to be well tolerated at
doses similar to those used in the present study. Such treatment
may potentially be used to improve the cognitive performances of
Down syndrome patients.
Materials and Methods
Animal housing, genotyping and treatment
Transgenic mice were generated on an FVB inbred background
[19]. Line 12 contains one copy of YAC152F7. The FVB
background that was used for micro-injection of the transgenic
fragments carries a recessive mutation (rd) inducing retinal
degeneration. To avoid an effect of rd on visual cues, we used
F1 male offspring from C57BL/6J females and transgenic FVB
males for the behavioral experiments and corresponding mRNA
experiments. Mice with heterozygous deletion of Dyrk1a [24] were
bred on a Swiss background and transgenic FVB males
(YACtg152F7) were crossed with Dyrk1a (+/2) females to
generate offspring with the four different genotypes. All animals
were bred under SPF conditions and were treated in compliance
with animal welfare policies from the Ministry of Agriculture (law
87848). JMD has the habilitation 75–369 for experiences on
vertebrates and these experiments have been approved by the
CREEA Nu4. Mice were genotyped as previously described
[20,23]. Treatment was prepared daily. In the first set of
experiments, mice were fed green tea ad libitum (1 g in 100 ml
water for 5 min at 100uC), corresponding to 0.6–1 mg EGCG per
day [30]; in the second set of experiments, mice were given a
solution of polyphenon 60 (0.8 g/l, Sigma), equivalent to 1.2 mg
per day.
Quantitative PCR experiments
mRNA was isolated (Microfastrack, Invitrogen) and reverse
transcribed (Ambion), and qRT-PCR (Light cycler, Roche) was
performed with primer sequences described in supplementary
table 2 in Data S1.
Protein extraction and western blotting
Adult mice (3 months old) were sacrificed by decapitation.
Brains were removed and dissected on ice to separate the cortex,
hippocampus and the thalamus/hypothalamus before being
frozen in liquid nitrogen and stored at 280uC. Individual
thalamus/hypothalamus were homogenized in NP-40 modified
lysis buffer [20 mM Tris-HCl (pH 7.4); 140 mM NaCl; 10%
glycerol; 1% NP-40; 2 mM EDTA] containing proteases inhibi-
tors (1 mM Pefa-Bloc; 2 mg/ml Aprotinin, leupeptin and pep-
statine; 5 mg/ml E64) and phophatase inhibitors (2 mM NaF;
1 mM Na3VO4 and PhosSTOP phosphatase inhibitors cocktail).
Protein concentration was determined using the Bio Rad Bradford
protein assay following the manufacturer’s instructions. For
western blotting, equal amounts of total proteins (30–50 mg) were
subjected to SDS-PAGE electrophoresis and transferred into
nitrocellulose membranes. The latter were blocked with TBS (Tris
buffered saline pH 7.5)-Tween 0,1% containing 5% of non-fat
dried milk and incubated with the Dyrk1A antibody (Abnova,
diluted 1:1000 in the blocking buffer) at 4uC overnight. Excess of
primary antibody was removed by rinsing with TBS-T, followed
by 1 h incubation with the species-appropriate horseradish
peroxidase-conjugated secondary antibody (Anti-mouse Ig diluted
1:40000 in the blocking solution) at room temperature. Immuno-
blots were subsequently probed with anti-ß actin antibody (Sigma,
diluted 1 :4000) as loading control. Signals were revealed by
enhanced chemiluminescence with the LAS300 Image Reader
and results analyzed with science Lab 2005 –MultiGauge software
(Life science Fujufilm).
MRI experiments
We performed in vivo MRI studies on animals from three
litters, using a horizontal 7T magnet connected to an INOVA
console (Varian, CA) and equipped with 120 mT/m gradient
coils and home-built 1H coils. Experimental conditions are
given in the supplementary methods section Data S1. Brain
structure volumes were estimated, using a visual guide visible on
each image set. MRI analysis protocols were established and
carried out independently by two investigators. The same
analysis was performed twice, once with each of two software
packages — WINMRI (Bruker) and AMIRA, (TGS Inc., San
Diego, CA) — and by each investigator, to evaluate the
reproducibility of volume measurements. Each 2D coronal data
set consisted of 41 images. As brain volume depends on age and
transgenic state, the number of slices taken was not constant and
was therefore not used to delimit the brain. In scans taken
between the appearance of the cerebellum and the disappear-
ance of the olfactory bulbs, brain volumes were extracted by
manually outlining regions of interest and multiplying by slice
thickness (0.5 mm).
GTP Rescue of Brain Phenotypes
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Working memory, exploratory activity and short-term habitu-
ation were assessed using a spontaneous alternation task: the
natural tendency of a mouse when placed in the Y-maze is to
move from one arm of the maze to another. During the test, mice
were placed at the centre of the maze and the sequence of entries
into the three arms was noted over a period of 10 min. (see supp
methods and supp Data S1).
Novel Object recognition
A novel object recognition test was used to assess the declarative
memory (see supp methods in Data S1). The performance is
measured on the whole retention session with: the time spent
exploring the two objects (N+F), the difference of exploration time
between the new object and the familiar object (N2F), the
difference of exploration time between the new object and the
familiar object in percent of the time spent exploring the two
objects (%(N2F)/(N+F)=1006(N2F)/(N+F)).
Memory of the object is considered to be present for a group on
a given period of time if animals spend more time in exploring the
new object than the familiar one, i.e. if (N2F) and %(N2F)/(N+F)
are higher than zero.
Data analysis
Data were analyzed using a Mann-Whitney-Wilcoxon test and
statistical significance was recorded for p,0.05. A second analysis
was used to assess the effects of treatment and genotype (two-way
ANOVA results are presented in supplementary Data S1).
Supporting Information
Data S1
Found at: doi:10.1371/journal.pone.0004606.s001 (0.15 MB
DOC)
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